Enliven CSO awarded options and RSUs

Enliven Therapeutics, Inc. reported an equity compensation award to its Chief Scientific Officer, Joseph P. Lyssikatos.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. reported an equity compensation award to its Chief Scientific Officer, Joseph P. Lyssikatos. On February 12, 2026, he was granted a stock option for 112,500 shares of common stock at an exercise price of $0.00 per share. According to the filing, one quarter of this option vests on February 12, 2027, with the remainder vesting in equal monthly installments over the following three years, so long as he continues as a service provider.

He also received 18,750 restricted stock units (RSUs), each representing one share of common stock. One quarter of these RSUs vest on March 1, 2027, with additional portions vesting on each June 1, September 1, December 1, and March 1 thereafter, subject to continued service. The filing also notes indirect ownership of 740,188 shares of common stock held through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Insider Trade Summary

Grant/Award: 131,250 shares

Grant/Award 3 txns

Insider Lyssikatos Joseph P

Role CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	112,500	$0.00	$0.00
Grant/Award	Common Stock	18,750	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 112,500 contracts (Direct); Common Stock — 18,750 shares (Direct); Common Stock — 740,188 shares (Indirect, See footnote)

Footnotes (3)

1. F1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
2. F2. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
3. F3. 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Enliven Therapeutics (ELVN) grant to its CSO?

Enliven granted Chief Scientific Officer Joseph P. Lyssikatos a stock option for 112,500 shares and 18,750 restricted stock units. Both awards vest over several years, contingent on his continued service to the company as a service provider.

How do Joseph Lyssikatos’s new stock options at ELVN vest?

The 112,500-share stock option vests 25% on February 12, 2027, with the remaining 75% vesting in equal monthly installments over the following three years. Vesting requires Joseph Lyssikatos to remain a service provider through each vesting date.

What is the vesting schedule for ELVN’s 18,750 RSU grant to its CSO?

The 18,750 restricted stock units vest 25% on March 1, 2027. The remaining units vest in equal installments each June 1, September 1, December 1, and March 1 thereafter, conditioned on Joseph Lyssikatos continuing as a service provider.

What indirect shareholdings in Enliven Therapeutics (ELVN) are reported?

The filing reports indirect ownership of 740,188 shares of Enliven common stock held by The Lyssikatos Revocable Trust 12/15/2011. Joseph Lyssikatos serves as trustee of this trust, which holds the shares on an indirect basis for him.

Does the Form 4 for ELVN show any stock sales by Joseph Lyssikatos?

The Form 4 does not report any stock sales. It records equity compensation awards, including a stock option and restricted stock units, and discloses indirect holdings through a revocable trust, but no dispose or sell transactions are identified in the transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 07:52 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyssikatos Joseph P

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		A		18,750(1)	A	$0	18,750(1)	D
Common Stock								740,188	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$27.16	02/12/2026		A		112,500		(3)	02/12/2036	Common Stock	112,500	$0	112,500	D

Explanation of Responses:

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.

2. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

3. 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

The Reporting Person is no longer deemed an executive officer under Section 16 after February 12, 2026.

	/s/ Ben Hohl, by power of attorney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.